₹280.85
−0.97%NSE close, 16 Nov 2026
−9.52%
Advanced Enzyme Technologies is a small cap company in the Healthcare sector, listed on NSE under the symbol ADVENZYMES. At ₹280.85 a share, the market values the whole company at ₹3,122 crore.
In FY26, it reported sales of ₹746 crore and a net profit of ₹169 crore, an operating margin of 30.7%. Over the last three years, sales grew 11.3% a year and net profit grew 16.9% a year.
The market values the company at 18.3 times its profit over the last twelve months and 1.88 times its book value; its return on equity is 10.3% and it has almost no borrowings.
Promoters hold 43.56% of the shares. Foreign institutions hold 26.65%, and domestic institutions, mutual funds among them, 1.89%.
Over the past year the share price has fallen 9.7%, and it is 33.0% below its 52-week high.
Companies of a similar size in the same sector include Aarti Pharmalabs, Healthcare Global Enterprises, Thyrocare Technologies and Suven Life Sciences.
₹ crore. Consolidated figures.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Advanced Enzyme Technologies | ₹280.85 | ₹3,122 cr | 18.3 | 10.3% | +16.20% | −9.69% |
| Aarti Pharmalabs | ₹986.75 | ₹8,948 cr | 35.4 | 11.2% | +45.90% | +16.93% |
| Healthcare Global Enterprises | ₹568.20 | ₹8,483 cr | 750.7 | 0.8% | +13.10% | −24.77% |
| Thyrocare Technologies | ₹509.65 | ₹8,112 cr | 56.3 | 26.1% | +25.10% | +15.46% |
| Suven Life Sciences | ₹268.90 | ₹7,598 cr | n/a |
Transcript
Extinguishment of Equity Shares
Link of Recording
Submission of application to the Stock Exchanges for Reclassification from Promoter Group to Public Category, pursuant to Regulation 31A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 [ Listing Regulations ]
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 161 | 158 | 155 | 146 | 169 | 167 | 186 | 185 | 172 | 203 | 190 | 215 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 107 | 102 | 103 | 104 | 114 | 122 | 129 | 124 | 123 | 140 | 139 | 142 |
| Operating profit | 53.8 | 55.4 | 51.2 | 42.4 | 55.3 | 45.6 | 56.4 | 60.1 | 49.4 | 63.2 | 51.0 | 72.1 |
| Operating margin | 33.4% | 35.1% | 33.1% | 29.0% | 32.7% | 27.3% | 30.4% | 32.5% | 28.7% | 31.1% | 26.9% | 33.6% |
| Other income | 14.4 | 9.5 | 7.0 | 9.6 | 7.7 | 8.7 | 8.9 | 10.3 | 8.5 | 7.2 | 13.0 | 8.7 |
| Interest | 0.7 | 0.9 | 0.9 | 0.9 | 0.9 | 0.8 | 0.8 | 0.7 | 0.6 | 0.6 | 0.6 | 1.2 |
| Depreciation | 8.6 | 9.3 | 8.6 | 8.9 | 9.0 | 10.1 | 9.6 | 10.1 | 10.2 | 10.2 | 9.9 | 10.9 |
| Profit before tax | 58.9 | 39.6 | 48.7 | 42.2 | 53.0 | 43.5 | 54.9 | 59.5 | 58.3 | 59.8 | 53.5 | 68.8 |
| Tax | 16.4 | 9.7 | 13.7 | 8.8 | 14.2 | 16.7 | 14.5 | 14.8 | 15.1 | 14.6 | 14.9 | 17.6 |
| Net profit | 41.8 | 28.3 | 34.2 | 32.8 | 37.7 | 26.5 | 39.9 | 43.3 | 42.5 | 43.0 | 37.1 | 48.3 |
| EPS (₹) | 3.74 | 2.53 | 3.05 | 2.94 | 3.36 | 2.37 | 3.57 | 3.87 | 3.80 | 3.84 | 3.31 | 4.33 |
₹ crore, financial years to March.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Sales | 420 | 444 | 502 | 529 | 541 | 624 | 637 | 746 |
| Expenses | 238 | 242 | 270 | 328 | 384 | 419 | 442 | 517 |
| Operating profit | 182 | 202 | 232 | 201 | 156 | 204 | 194 | 229 |
| Operating margin | 43.4% | 45.6% | 46.1% | 38.0% | 28.9% | 32.8% | 30.5% | 30.7% |
| Other income | 5.0 | 5.6 | 8.9 | 6.4 | 25.5 | 36.7 | 33.0 | 34.8 |
| Interest | 3.9 | 3.0 | 1.6 | 1.8 | 2.4 | 2.9 | 3.6 | 2.6 |
| Depreciation | 21.1 | 25.8 | 28.4 | 35.0 | 35.0 | 35.2 | 36.6 | 40.1 |
| Profit before tax | 162 | 179 | 210 | 171 | 140 | 188 | 187 | 233 |
| Tax | 46.1 | 46.1 | 58.9 | 47.3 | 36.5 | 50.9 | 53.4 | 58.9 |
| Net profit | 111 | 129 | 146 | 120 | 106 | 133 | 131 | 169 |
| EPS (₹) | 9.95 | 11.58 | 13.09 | 10.70 | 9.44 | 11.93 | 11.72 | 15.08 |
₹ crore, at each year's end and the latest half year.
| Line | FY23 | FY24 | FY25 | FY26 | Sep 2026 |
|---|---|---|---|---|---|
| Shareholders’ equity | 1,235 | 1,324 | 1,421 | 1,632 | 1,665 |
| Borrowings | 13.2 | 25.1 | 21.5 | 20.5 | 21.8 |
| Total liabilities | 138 | 164 | 153 | 156 | 186 |
| Fixed assets | 273 | 277 | 293 | 276 | 308 |
| Investments | 0.2 | 0.2 | 0.1 | 0.1 | 1.0 |
| Cash and equivalents | 96.4 | 114 | 94.2 | 109 | 159 |
| Total assets | 1,422 | 1,535 | 1,621 | 1,839 | 1,906 |
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 124 | 143 | 157 | 77.2 |
| From investing | −26.1 | −89.1 | −74.1 | 44.3 |
| From financing | −27.4 | −72.5 | −70.4 | −72.3 |
| Spent on fixed assets | −28.1 | −33.8 | −52.2 | −51.6 |
| Free cash flow | 95.4 | 109 | 105 | 25.6 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Net margin | 26.5% | 29.1% | 29.1% | 22.6% | 19.5% | 21.4% | 20.6% | 22.6% |
| Operating margin | 43.4% | 45.6% | 46.1% | 38.0% | 28.9% | 32.8% | 30.5% | 30.7% |
| Return on equity | – | – | – | – | 8.6% | 10.1% | 9.2% | 10.3% |
| Return on capital employed | – | – | – | – | 11.4% | 14.1% | 13.2% | 14.2% |
| Return on assets | – | – | – | – | 7.4% | 8.7% | 8.1% | 9.2% |
| Debt to equity | – | – | – | – | 0.01 | 0.02 | 0.02 | 0.01 |
| Interest coverage | 42.90 | 59.90 | 133.30 | 96.00 | 59.30 | 65.10 | 53.60 | 89.40 |
| Debt to assets | – | – | – | – | 0.01 | 0.02 | 0.01 | 0.01 |
| Current ratio | – | – | – | – | 9.31 | 7.61 | 9.09 | 9.78 |
| Quick ratio | – | – | – | – | 7.71 | 6.22 | 7.47 | 8.12 |
| Cash ratio | – | – | – | – | 1.24 | 1.07 | 0.97 | 1.02 |
| Asset turnover | – | – | – | – | 0.38 | 0.41 | 0.39 | 0.41 |
| Fixed asset turnover | – | – | – | – | 1.98 | 2.26 | 2.17 | 2.70 |
| Inventory turnover | – | – | – | – | – | 1.00 | 1.00 | 1.10 |
| Receivables turnover | – | – | – | – | 5.40 | 6.30 | 5.50 | 5.10 |
| Gross margin | – | – | – | – | – | 76.8% | 76.2% | 74.1% |
| Cash from operations to profit | – | – | – | 103.0% | – | – | 109.0% | 93.0% |
| Effective tax rate | 28.4% | 25.7% | 28.0% | 27.6% | 26.0% | 27.1% | 28.5% | 25.3% |
| -84.2% |
| +30.40% |
| +39.45% |
| Nephrocare Health Services | ₹642.00 | ₹6,456 cr | 50.4 | 10.8% | n/a | n/a |
|---|
| Sun Pharma Advanced Research Company | ₹195.84 | ₹6,355 cr | 3.9 | 113.4% | +282.10% | +45.52% |
|---|
| Senores Pharmaceuticals | ₹1,147.80 | ₹5,286 cr | 38.2 | 13.8% | +18.90% | +42.61% |
|---|
| Supriya Lifescience | ₹622.30 | ₹5,008 cr | 28.3 | 14.3% | +3.20% | −20.15% |
|---|
Quarterly EarningsRelease dated October 31, 2026
The Board of Directors at their meeting held today i.e. October 31, 2026 have analyzed the requests received from the promoter group members for their reclassification from promoter group category to public category shareholders, pursuant to Regulation 31A of SEBI (Listing…
The financial results for the period ended September 30, 2026.
Schedule of meet
Intimation of receipt of request from promoter group member for reclassificationfrom Promoter Group category to Public category shareholders under Regulation 31Aof the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation of receipt of request from promoter group member for reclassification from Promoter Group category to Public category shareholder under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)
Intimation of receipt of request from few promoter group members for reclassification from Promoter Group category to Public category shareholder under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)